Present and future of recombinant gonadotropins in reproductive medicine

Current Pharmaceutical Biotechnology

Volumn 13, Issue 3, 2012, Pages 379-391

  de Leo, Vincenzo ^a   Musacchio, Maria Concetta ^a   di Sabatino, Alessandra ^a   Tosti, Claudia ^a   Morgante, Giuseppe ^a   Petraglia, Felice ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Induction of ovulation; Infertility; Recombinant gonadotropins

Indexed keywords

ANDROGEN; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; GONADORELIN ANTAGONIST; GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; MEROPUR; NAFARELIN; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT FOLLITROPIN PLUS RECOMBINANT LUTEINIZING HORMONE; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN; UNCLASSIFIED DRUG; UROFOLLITROPIN;

ANDROGEN SYNTHESIS; ANEUPLOIDY; BIRTH RATE; CELL TRANSFORMATION; CLINICAL EFFECTIVENESS; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; ESTRADIOL BLOOD LEVEL; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR PHASE; GLYCOSYLATION; GRANULOSA CELL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; IN VIVO STUDY; INFERTILITY THERAPY; INJECTION SITE REACTION; LIVE BIRTH; LONG TERM CARE; LOW DRUG DOSE; LUTEAL PHASE; MALE INFERTILITY; META ANALYSIS (TOPIC); MULTIPLE PREGNANCY; NONHUMAN; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY CYCLE; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PHARMACODYNAMICS; PHARMACOKINETICS; POSTMENOPAUSE; PREGNANCY RATE; PREMEDICATION; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINANT DNA TECHNOLOGY; REPRODUCTION; REVIEW; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON DENSITY; TREATMENT DURATION;

ANIMALS; ANOVULATION; FEMALE; GONADOTROPINS; HUMANS; INFERTILITY, FEMALE; MALE; OVULATION INDUCTION; RECOMBINANT PROTEINS; REPRODUCTIVE MEDICINE;

MAMMALIA;

EID: 84857749260     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799361918     Document Type: Review

References (106)

1. Lunenfeld, B. Historical perspectives in gonadotrophin therapy. Hum. Reprod. Update, 2004, 10(6), 453-467.
2. The European Recombinant LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle stimulating hormone (FSH)-induced follicular development in LH and FSH-deficient anovulatory women: a dose-finding study. J. Clin. Endocrinol. Metab., 1998, 83(5), 1507-1514.
3. Krause, B.T.; Ohlinger, R.; Haase, A. Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review. Biologics, 2009, 3, 337-347.
4. The Practice Committee of the American Society for Reproductive Medicine, Birmingham, Alabama. Gonadotropin preparations: past, present, and future perspectives. Fertil. Steril., 2008, 90(3), S13-S20.
5. Foresta, G.; Selice, R.; Ferlin, A.; Garolla, A. Recombinant FSH in the treatment of oligozoospermia. Expert. Opin. Biol. Ther., 2009, 9(5), 659-666.
6. Isidori, A.; Latini, M.; Romanelli, F. Treatment of male infertility. Contraception, 2005, 72(4), 314-318.
7. Schipper, I.; Hop W.C.; Fauser, B.C. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. J. Clin. Endocrinol. Metab., 1998, 83(4), 1292-1298.
8. Gougeon, A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr. Rev., 1996, 17(2), 121-755.
9. McGee, E.A.; Hsueh, A.J.W. Initial and cyclic recruitment of ovarian follicles. Endocr. Rev., 2000, 21(2), 200-214.
10. Sullivan, M.W.; Stewart-Akers, A.; Krasnow, J.S.; Berga S.L.; Zeleznik A.J. Ovarian responses in women to recombinant folliclestimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J. Clin. Endocrinol. Metab., 1999, 84(1), 228-232.
11. Vendola, K.A.; Zhou, J.; Adesanya, O.O.; Weil, S.J.; Bondy, C.A. Androgens stimulate early stages of follicular growth in the primate ovary. J. Clin. Invest., 1998, 101(12), 2622-2629.
12. Yamoto, M.; Shima, K.; Nakano, R. Gonadotrophin receptors in human ovarian follicles and corpora lutea throughout the menstrual cycle. Hormone Res., 1992, 37(suppl.1), 5-11.
13. Filicori, M.; Cognigni, G.E.; Taraborrelli, S.; Spettoli, D.; Ciampaglia, W.; de Fatis, C.T.; Pocognoli, P. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J. Clin. Endocrinol. Metab. 1999, 84(8), 2659-2663.
14. Hoff, J.D.; Quigley, M.E.; Yen, S.S. Hormonal dynamics at midcycle: a reevaluation. J. Clin. Endocrinol. Metab., 1983, 57(4), 792-796.
15. March, C.M., Goebelsmann, U.; Nakamura, R.M., Mishell, D.R. Jr. Roles of estradiol and progesterone in eliciting the midcycle luteinizing hormone and follicle-stimulating hormone surges. J. Clin. Endocrinol. Metab., 1979, 49(4), 507-513.
16. Karligiotou, E.; Kollia, P.; Kallitsaris, A.; Messinis, I.E. Expression of human serum albumin (HSA) mRNA in human granulose cells: potential correlation of the 95 amino acid long carboxyl terminal of HSA to gonadotrophin surge-attenuating factor. Hum. Reprod., 2006, 21(3), 645-650.
17. Fowler, P.A.; Sorsa-Leslie, T.; Harris, W.; Mason, H.D. Ovarian gonado-trophin surge-attenuating factor (GnSAF): where are we after 20 years of research? Reproduction, 2003, 126(6), 689-699.
18. Crowe, S.J.; Cushing, H.; Homans, J. Experimental hypophysectomy. Bull. John Hopkins Hospt., 1910, 21, 127-167.
19. Fevold, S.L.; Hisaw, F.L.; Leonard, S.L. The Gonad-stimulating and the luteinizing hormones of the anterior lobe of the hypophysis. Am. J. Physiol., 1931, 97, 291-301.
20. Ascheim, S.; Zondek, B. Hypophysenvorderlappen hormone und ovarialhormone im Harn von Schwangeren. Klin Wochenschr, 1927, 6, 13-21.
21. Seegar-Jones, G.E.; Gey, G.O.; Ghisletta, M. Hormone production by placental cells maintained in continuous culture. Bull. John Hopkins Hosp., 1943, 72, 26-38.
22. Midgley, A.R., Pierce, G.B. Immunohistochemical localization of human chorionic gonadotropin. J. Exp. Med., 1962, 115, 289-294.
23. Lunenfeld B. Treatment of anovulation by human gonadotropins. J. Int. Fed. Gynaecol. Obstet. 1963, 1, 153.27.
24. Rosenberg, E.; Coleman, J.; Damani, M.; Garcia, C.R. Clinical effect of post menopausal gonadotropin. J. Clin. Endocrinol. Metab., 1962, 23, 181-189.
25. Gemzell, C.A.; Diczfalusy, E.; Tillinger, G. Clinical effect of human pituitary follicle stimulating hormone (FSH). J. Clin. Endcrinol. Metab., 1958, 18(12), 1333-1348.
26. Cochius, J.I.; Mack, K.; Burns, R.J. Creutzfeld-Jakob disease in a recipient human pituitary derived gonadotrophin. Aust. NZ J Med., 1990, 20, 592-596.
27. Dumble, L.D.; Klein, R.D. Creutzfeld-Jakob disease legacy for Australian women treated with human pituitary gonadotropins. Lancet, 1992, 3, 340(8823), 847-848.
28. Giudice, E.; Crisci, C.; Eshkol, A., Papoian, R. Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins. Hum. Reprod., 1994, 9(12), 2291-2299.
29. Howles, C.M. Genetic engineering of human FSH (Gonal-F). Hum. Reprod. Update, 1996, 2(2), 172-191.
30. Olijve, W.; de Boer, W.; Mulders, J.W.; vanWezenbeek, P.M. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol. Hum. Reprod., 1996, 2(5), 371-382.
31. Bagatti, G.; Crisci, C.; Datola, A.; Gostoli, G.; Mascia, M.; Polletta, P.; Roncalli, G.; Simoni, P. Characterization and comparison of recombinant human follicle-stimulating hormones. J. Clin. Res., 2001, 4, 91-104.
32. Brinsden, P.; Akagbosu, F.; Gibbons, L.M.; Lancaster, S.; Gourdon, D.; Engrand, P.; Loumaye, E. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization embryo transfer. Fertil Steril., 2000, 73(1), 114-116.
33. The European Recombinant Human Chorionic Gonadotrophin Study Group. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment-recombinant HCG versus urinary HCG. Hum Reprod., 2000, 15 (7), 1446-1451.
34. Vaitukaitis, J.L.; Ross, G.T.; Braunstein, G.D.; Rayford, P.L. Gonadotropins and their subunits: basic and clinical studies. Recent Prog. Horm. Res., 1976, 32, 289-331.
35. Padmanabhan, V.; Lang, L.L.; Sonstein, J.; Kelch, R.P.; Beitins, I.Z. Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. J. Clin. Endocrinol. Metab., 1988, 67(3), 465-473.
36. Anobile, C.J.; Talbot, J.A.; McCann, S.J.; Padmanabhan, V.; Robertson, W.R. Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state. Mol. Hum. Reprod., 1998, 4 (7), 631-639.
37. Lo Conte, J.Y.; Porchet, H.C.; Beltrami, V.; Khan, A.; Toon, S.; Rowland M. Clinical pharmacology of recombinant human follicle- stimulating hormone: II. Single doses and steady-state pharmacokinetics. Fertil. Steril., 1994, 61(4), 679-686.
38. Mannaerts, B.M.; Rombout, F.; Out, H.J.; Coelingh Bennink, H. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum. Reprod. Update, 1996, 2(2), 153-161.
39. Pang, S.; Kaplan, B.; Karande, V.; Westphal, L.M.; Scott, R.; Givens, C.; Sacks, P.; Follistim Pen Trade Mark COH Study Group. Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod. Biomed. Online 2003, 7(3), 319-326.
40. WHO scientific group. Advances in methods of fertility regulation: report of a WHO scientific group. World Health Organ. Tech. Rep. Ser., 1973, 1-42.
41. Burgues, S. the Spanish Collaborative Group on Female Hypogonadotropic Hypogonadism. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum. Reprod., 2001, 16, (12) 2525-2532.
42. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil. Steril., 2008, 89(3), 505-522.
43. Homburg, R. Clomiphene citrate-end of an era? A mini-review. Hum. Reprod., 2005, 20(8), 2043-2051.
44. Wang C.F. and Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil. Steril., 1980, 33 (5), 479-486.
45. Hornnes, R.; Giroud, D.; Howles, C.; Loumaye, E. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman. Fertil Steril, 1993, 60(4), 724-726.
46. Calaf Alsina J.; Ruiz Balda, J.A.; Romeu Sarrio, A.; Caballero Fernandez, V.; Cano Trigo, I.; Gomez Parga, J.L. González Batres, C.; Rodríguez Escudero, F.J. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG, 2003, 110(12), 1072-1077.
47. Christin-Maitre, S.; Hugues, J.N. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod., 2003, 18 (8), 1626-1631.
48. Recombinant Human FSH study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil. Steril., 1995, 63 (1), 77-86.
49. Out, H.J.; Mannaerts, B.M.; Driessen, S.G.; Bennink, H.J. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod., 1995, 10(10), 2534-2540.
50. Daya, S.; Gunby, J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproductive cycles (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Update quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2002.
51. van Wely, M.; Westergaard, L.G.; Bossuyt, P.M.; van der Veen, F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil. Steril., 2003, 80(5), 1086-1093.
52. Andersen, A.N.; Devroey, P.; Arce, J.C. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum. Reprod., 2006, 21(12), 3217-3227.
53. Coomarasamy, A.; Afnan, M.; Cheema, D.; van der Veen, F.; Bossuyt, P.M.; van Wely, M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum. Reprod., 2008, 23(2), 310-315.
54. Al-Inany, H.G.; Abou-Setta, A.M.; Aboulghar, M.A.; Mansour, R.T.; Serour, G.I. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod. Biomed. Online, 2008, 16(1), 81-88.
55. Out, H.J.; Lindenberg, S.; Mikkelsen, A.L.; Eldar-Geva, T.; Healy, D.L.; Leader, A.; Rodriguez-Escudero, F.J.; Garcia-Velasco, J.A.; Pellicer, A. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum. Reprod., 1999, 14(3), 622-627.
56. Out, H.J.; David, I.; Ron-El, R.; Friedler, S.; Shalev, E.; Geslevich, J.; Dor, J.; Shulman, A.; Ben-Rafael, Z.; Fisch, B.; Dirnfeld, M. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum. Reprod., 2001, 16(6), 1104-1109.
57. Hoomans, E.H.; Mulder, B.B.; Asian Purgeon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. J. Assist. Reprod. Genet., 2002, 19(10), 470-476.
58. Out, H.J.; Braat, D.D.; Lintsen, B.M.; Gurgan, T.; Bukulmez, O.; Gökmen, O.; Keles, G.; Caballero, P.; González, J.M.; Fábregues, F.; Balasch, J.; Roulier, R. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum. Reprod., 2000, 15(1), 29-35.
59. Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil. Steril., 2001, 76(5), 950-956.
60. Wikland, M.; Bergh, C.; Borg, K.; Hillensjö, T.; Howles, C.M.; Knutsson, A.; Nilsson, L.; Wood, M. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum. Reprod., 2001, 16 (8), 1676-1681.
61. Berkkanoglu, M.; Ozgur, K. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil. Steril., 2010, 94(2), 662-665.
62. McClamrock, H.D. Recombinant gonadotropins. Clin. Obstet. Gynecol., 2003, 46(2), 298-316.
63. Porchet, H.; Le Cotonnec, J.Y.; Neuteboom, B.; Canali, S.; Zanolo, G. Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone. J. Clin. Endocrinol. Metab., 1995, 80(2), 667-673.
64. Balen, A.H.; Braat, D.D.M.; West, C.; Patel, A.; Jacobs, H.S. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum. Reprod., 1994, 9(8), 1563-1570.
65. Martin, K.A.; Hall, J.E.; Adams, J.M.; Cowley, W.F. Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropinreleasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J. Clin. Endocrinol. Metab., 1993, 77(1), 125-129.
66. Schoot, D.C.; Harlin, J.; Shoham, Z.; Mannaerts, B.M.; Lahlou, N.; Bouchard, P.; Bennink, H.J.; Fauser, B.C. Recombinant human follicle- stimulating hormone and ovarian response in gonadotrophindeficient women. Hum. Reprod., 1994, 9(7), 1237-1242
67. Shoham, Z.; Balen, A.; Patel, A.; Jacobs, H.S. Results of ovulation induction using human menopausal gonadotropin or purified follicle- stimulating hormone in hypogonadotropic hypogonadism patients. Fertil. Steril., 1991, 56(6), 1048-1053.
68. Schoot, D.C.; Coelingh Bennink, H.J.; Mannaerts, B.M.; Lamberts, S.W.; Bouchard, P.; Fauser, B.C. Human recombinant folliclestimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. J. Clin. Endocrinol. Metab., 1992, 74(6), 1471-1473.
69. Shoham, Z.; Mannaerts, B.; Insler, V.; Coelingh-Bennink, H. Induction of follicular growth using recombinant human folliclestimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil. Steril., 1993, 59(4), 738-742.
70. Balasch, J.; Miró, F.; Burzaco, I.; Casamitjana, R.; Civico, S.; Ballescá, J.L.; Puerto, B.; Vanrell, J.A. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum. Reprod., 1995, 10(7), 1678-1683.
71. Kousta, E.; White, D.M.; Piazzi, A.; Loumaye, E.; Franks, S. Successful induction of ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome. Hum. Reprod., 1996, 11, 70-71.
72. Shoham, Z.; Smith, H.; Yeko, T.; O'Brien, F.; Hemsey, G.; O'Dea, L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, doubleblind, placebo-controlled, proof-of-efficacy study. Clin. Endocrinol., 2008, 69(3), 471-478.
73. Westergaard, L.G.; Laursen, S.B.; Andersen, C.Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum. Reprod., 2000, 15(5), 1003-1008.
74. Weghofer, A.; Munné, S.; Brannath, W.; Chen, S.; Barad, D.; Cohen, J.; Gleicher, N. The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles. Fertil. Steril., 2009, 92(3), 937-942.
75. Kolibianakis, E.M.; Kalogeropoulou, L.; Griesinger, G.; Papanikolaou, E.G.; Papadimas, J.; Bontis, J.; Tarlatzis, B.C. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum. Reprod. Update, 2007, 13(5), 445-452.
76. Nyboeandersen, A.; Humaidan, P.; Fried, G.; Hausken, J.; Antila, L.; Bangsbøll, S.; Rasmussen, P.E.; Lindenberg, S.; Bredkjaer, H.E.; Meinertz, H.; Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum. Reprod., 2008, 23(2), 427-434.
77. Filicori, M.; Cognigni, G.E.; Taraborrelli, S.; Spettoli, D.; Ciampaglia, W.; Tabarelli De Fatis, C.; Pocognoli, P.; Cantelli, B.; Boschi, S. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controller ovarian stimulation. J. Clin. Endocrinol. Metab., 2001, 86 (1), 337-343.
78. Filicori, M.; Cognigni, G.E.; Tabarelli, C.; Pocognoli, P.; Taraborrelli, S.; Spettoli, D.; Ciampaglia, W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J. Clin. Endocrinol. Metab., 2002, 87 (3), 1156-1161.
79. Hillier, S.G. In: The New Frontier in Ovulation Induction. Jacobs, H.S., Ed., Parthenon: Carnforth, 2001:p. 39-47.
80. Balasch J. In: Textbook of Assisted Reproductive Techniques. Gardner, D.K.; Weismann, A.; Howles, C.M.; Shoham, Z. Ed., Malden: Martin Dunitz, 2001; p. 425-46.
81. Shoham, Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil. Steril., 2002, 77, 1170-1177.
82. Loumaye, E.; Engrand, P.; Shoham, Z.; Hillier, S.G.; Baird, D.T. Clinical evidence for an LH ceiling? Hum. Reprod., 2003, 18(12), 2719-2720.
83. Durnerin, C.I.; Erb, K.; Fleming, R.; Hillier, H.; Hillier, S.G.; Howles, C.M.; Hugues, J.N.; Lass, A.; Lyall, H.; Rasmussen, P.; Thong, J.; Traynor, I.; Westergaard, L.; Yates, R.; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum. Reprod., 2008, 23(2), 421-426.
84. Pacchiarotti, A.; Sbracia, M.; Frega, A.; Selman, H.; Rinaldi, L.; Pacchiarotti, A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil. Steril., 2010, May 25. [Epub ahead of print]
85. Stenman, U.H.; Tiitinen, A.; Alfthan, H.; Valmu, L. The classification, functions and clinical use of different isoforms of HCG. Hum. Reprod. Update, 2006, 12(6), 769-784.
86. The International Recombinant Human Chorionic Gonadotropin Study Group. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil. Steril., 2001, 75(6), 1111-1118.
87. Chang, P.; Kenley, S.; Burns, T.; Denton, G.; Currie, K.; DeVane, G.; O'Dea, L. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilizationembryo transfer. Fertil Steril, 2001, 76, 67-74.
88. Koichi, K.; Yukiko, N.; Shima, K.; Sachiko, S. Efficacy of lowdose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol. J. Assist. Reprod. Genet., 2006, 23(5), 223-228.
89. Serafini, P.; Yadid, I.; Motta, E.L.; Alegretti, J.R.; Fioravanti, J.; Coslovsky, M. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril., 2006, 86(4), 830-838.
90. Tesarik, J.; Mendoza, C. Nongenomic effects of 17b-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J. Clin. Endocrinol. Metab., 1995, 80 (4), 1438-1443.
91. Tesarik, J.; Mendoza, C. Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Hum. Reprod. Update, 1997, 3, 95-100.
92. Fleming, R.; Lloyd, F.; Herbert, M.; Fenwick, J.; Griffiths, T.; Murdoch, A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum. Reprod., 1998, 13 (7), 1788-1792.
93. Fleming, R.; Rehka, P.; Deshpande, N.; Jamieson, M.E.; Yates, R.W.S.; Lyall, H.L. Suppression of LH during ovarian stimulation effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum. Reprod., 2000, 15(7), 1440-1445.
94. Esposito, M.A.; Barnhart, K.T.; Coutifaris, C.; Patrizio, P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle stimulating hormone. Fertil. Steril., 2001, 75 (3), 519-523.
95. Selman, H.; Pacchiarotti, A.; El-Danasouri, I. Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcome. Fertil. Steril., 2009, Nov 23. [Epub ahead of print]
96. Mannaerts, B.; Fauser, B.; Lahlou, N.; Harlin, J.; Shoham, Z.; Bennink, H.C.; Bouchard, P. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism. Fertil. Steril., 1996, 65(2), 406-410.
97. Bouloux, P.M.; Nieschlag, E.; Burger, H.G.; Skakkebaek, N.E.; Wu, F.C.; Handelsman, D.J.; Baker, G.H.; Ochsenkuehn, R.; Syska, A.; McLachlan, R.I.; Giwercman, A.; Conway, A.J.; Turner, L.; van Kuijk, J.H.; Voortman, G. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J. Androl., 2003, 24(4), 604-611.
98. Paradisi, R.; Busacchi, P.; Seracchioli, R.; Porcu, E.; Venturoli, S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertil. Steril., 2006, 86(3), 728-731.
99. Foresta, C.; Bettella, A.; Merico, M.; Garolla, A.; Ferlin, A.; Rossato, M. Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility. Fertil Steril., 2002, 77(2), 238-244.
100. Foresta, C.; Betella, A.; Garolla, A.; Ambrosini, G.; Ferlin, A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril., 2005, 84(7), 654-661.
101. Foresta, C.; Selice, R.; Ferlin, A.; Arslan, P.; Garolla, A. Hormonal treatment of male infertility: FSH. Reprod. BioMed. Online, 2007, 15(26), 666-672.
102. Piomboni, P.; Serafini, F.; Gambera, L.; Musacchio, C.; Collodel, G.; Morgante, G.; De Leo, V. Sperm aneuploidies after human recombinant follicle stimulating hormone therapy in infertile males. Reprod. Biomed. Online, 2009, 18(5), 622-629.
103. Collodel, G.; Capitani, S.; Baccetti, B.; Pammolli, A.; Moretti, E. Sperm aneuploidies and low progressive motility. Hum. Reprod., 2007, 22(7), 1893-1898.
104. Ruwanpura, S.M.; McLachlan, R.I.; Matthiesson, K.L.; Meachem, S.J. Gonadotrophins regulate germ cell survival, not proliferation, in normal adult men. Hum. Reprod., 2008, 23(2), 403-411.
105. Perlman, S.; van den Hazel, B.; Christiansen, J.; Gram-Nielsen, S.; Jeppesen, C.B.; Andersen, K.V.; Halkier, T.; Okkels, S.; Schambye, H.T. Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J. Clin. Endocrinol. Metab., 2003, 88(7), 3227-3235.
106. Devroey, P.; Fauser, B.C.; Platteau, P.; Beckers, N.G.; Dhont, M.; Mannaerts, B.M. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J. Clin. Endocrinol. Metab., 2004, 89(5), 2062-2070.